哮喘中的细胞因子
2019/05/10
摘要
哮喘是一种慢性炎症性气道疾病，与2型细胞因子白细胞介素-4（IL-4），IL-5和IL-13相关，促进气道嗜酸性粒细胞增多，粘液高分泌，支气管高反应性（BHR）和免疫球蛋白E（IgE）合成。然而，只有一半的哮喘患者表现出加剧的2型反应的迹象。“低2型”哮喘具有不同的免疫特征：气道中性粒细胞增多，肥胖相关的全身性炎症，或者在某些情况下，免疫激活的迹象很少。本文中，我们回顾了驱动哮喘的细胞因子网络，将它们置于细胞环境中，并结合临床细胞因子靶向治疗的见解。我们在日益认识到疾病异质性的背景下讨论已确立的和新兴的理论，并认为在开发新的和改进已有治疗方法时更需要了解哮喘病理的各种潜在机制。
The Cytokines of Asthma.
Lambrecht BN, Hammad H, Fahy JV.
Abstract
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overproduction, bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis. However, only half of asthma patients exhibit signs of an exacerbated Type 2 response. "Type 2-low" asthma has different immune features: airway neutrophilia, obesity-related systemic inflammation, or in some cases, few signs of immune activation. Here, we review the cytokine networks driving asthma, placing these in cellular context and incorporating insights from cytokine-targeting therapies in the clinic. We discuss established and emerging paradigms in the context of the growing appreciation of disease heterogeneity and argue that the development of new and improved therapeutics will require understanding the diverse mechanisms underlying the spectrum of asthma pathologies.
哮喘是一种慢性炎症性气道疾病，与2型细胞因子白细胞介素-4（IL-4），IL-5和IL-13相关，促进气道嗜酸性粒细胞增多，粘液高分泌，支气管高反应性（BHR）和免疫球蛋白E（IgE）合成。然而，只有一半的哮喘患者表现出加剧的2型反应的迹象。“低2型”哮喘具有不同的免疫特征：气道中性粒细胞增多，肥胖相关的全身性炎症，或者在某些情况下，免疫激活的迹象很少。本文中，我们回顾了驱动哮喘的细胞因子网络，将它们置于细胞环境中，并结合临床细胞因子靶向治疗的见解。我们在日益认识到疾病异质性的背景下讨论已确立的和新兴的理论，并认为在开发新的和改进已有治疗方法时更需要了解哮喘病理的各种潜在机制。
(中日友好医院呼吸与危重症医学科 顾宪民 摘译 林江涛 审校)
(Immunity. 2019 Apr 16;50(4):975-991. doi: 10.1016/j.immuni.2019.03.018.)
(Immunity. 2019 Apr 16;50(4):975-991. doi: 10.1016/j.immuni.2019.03.018.)
The Cytokines of Asthma.
Lambrecht BN, Hammad H, Fahy JV.
Abstract
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overproduction, bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis. However, only half of asthma patients exhibit signs of an exacerbated Type 2 response. "Type 2-low" asthma has different immune features: airway neutrophilia, obesity-related systemic inflammation, or in some cases, few signs of immune activation. Here, we review the cytokine networks driving asthma, placing these in cellular context and incorporating insights from cytokine-targeting therapies in the clinic. We discuss established and emerging paradigms in the context of the growing appreciation of disease heterogeneity and argue that the development of new and improved therapeutics will require understanding the diverse mechanisms underlying the spectrum of asthma pathologies.
上一篇：
成纤维细胞形成的纤维胶原组织缺陷有助于哮喘患者气道重塑
下一篇：
气道嗜酸性粒细胞在哮喘气道重塑中的作用：MMP-10和MET的作用
